메뉴 건너뛰기




Volumn 98, Issue 5, 2013, Pages 578-588

Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: A report from the japanese pediatric leukemia/lymphoma study group

(20)  Tomizawa, Daisuke a   Tawa, Akio b   Watanabe, Tomoyuki c   Saito, Akiko Moriya d   Kudo, Kazuko e   Taga, Takashi f   Iwamoto, Shotaro g   Shimada, Akira h   Terui, Kiminori i   Moritake, Hiroshi j   Kinoshita, Akitoshi k   Takahashi, Hiroyuki l   Nakayama, Hideki m   Kiyokawa, Nobutaka n   Isoyama, Keiichi o   Mizutani, Shuki a   Hara, Junichi p   Horibe, Keizo d   Nakahata, Tatsutoshi q   Adachi, Souichi r  


Author keywords

Acute myeloid leukemia; Acute respiratory distress syndrome; Early death; Infants

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

EID: 84892916628     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1429-2     Document Type: Article
Times cited : (49)

References (21)
  • 3
    • 0028057282 scopus 로고
    • Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes
    • Sorensen PH, Chen CS, Smith FO, Arthur DC, Domer PH, Bernstein ID, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Investig. 1994;93(1):429-37.
    • (1994) J Clin Investig , vol.93 , Issue.1 , pp. 429-437
    • Sorensen, P.H.1    Chen, C.S.2    Smith, F.O.3    Arthur, D.C.4    Domer, P.H.5    Bernstein, I.D.6
  • 4
    • 0026654207 scopus 로고
    • The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children
    • Lion T, Haas OA, Harbott J, Bannier E, Ritterbach J, Jankovic M, et al. The translocation t(1;22)(p13;q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood. 1992;79(12):3325-30.
    • (1992) Blood , vol.79 , Issue.12 , pp. 3325-3330
    • Lion, T.1    Haas, O.A.2    Harbott, J.3    Bannier, E.4    Ritterbach, J.5    Jankovic, M.6
  • 5
    • 40449124892 scopus 로고    scopus 로고
    • Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement
    • Hauer J, Tosi S, Schuster FR, Harbott J, Kolb HJ, Borkhardt A. Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement. Pediatr Blood Cancer. 2008;50(4):921-3.
    • (2008) Pediatr Blood Cancer , vol.50 , Issue.4 , pp. 921-923
    • Hauer, J.1    Tosi, S.2    Schuster, F.R.3    Harbott, J.4    Kolb, H.J.5    Borkhardt, A.6
  • 6
    • 84859646588 scopus 로고    scopus 로고
    • Favorable outcome in infants with AML after intensive first- and second-line treatment: An AMLBFM study group report
    • Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: An AMLBFM study group report. Leukemia. 2012;26(4):654-61.
    • (2012) Leukemia , vol.26 , Issue.4 , pp. 654-661
    • Creutzig, U.1    Zimmermann, M.2    Bourquin, J.P.3    Dworzak, M.N.4    Kremens, B.5    Lehrnbecher, T.6
  • 7
    • 28544447722 scopus 로고    scopus 로고
    • Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
    • Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-8.
    • (2005) Leukemia , vol.19 , Issue.12 , pp. 2130-2138
    • Gibson, B.E.1    Wheatley, K.2    Hann, I.M.3    Stevens, R.F.4    Webb, D.5    Hills, R.K.6
  • 8
    • 0036786901 scopus 로고    scopus 로고
    • The world health organization (WHO) classification of the myeloid neoplasms
    • Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.
    • (2002) Blood , vol.100 , Issue.7 , pp. 2292-2302
    • Vardiman, J.W.1    Harris, N.L.2    Brunning, R.D.3
  • 9
    • 78751572651 scopus 로고    scopus 로고
    • Flow cytometric analysis of de novo acute myeloid leukemia in childhood: Report from the japanese pediatric leukemia/lymphoma study group
    • Ohta H, Iwamoto S, Kiyokawa N, Tsurusawa M, Deguchi T, Takase K, et al. Flow cytometric analysis of de novo acute myeloid leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol. 2011;93(1):135-7.
    • (2011) Int J Hematol , vol.93 , Issue.1 , pp. 135-137
    • Ohta, H.1    Iwamoto, S.2    Kiyokawa, N.3    Tsurusawa, M.4    Deguchi, T.5    Takase, K.6
  • 10
    • 69849101233 scopus 로고    scopus 로고
    • Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese childhood AML cooperative study group
    • Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-13.
    • (2009) J Clin Oncol , vol.27 , Issue.24 , pp. 4007-4013
    • Tsukimoto, I.1    Tawa, A.2    Horibe, K.3    Tabuchi, K.4    Kigasawa, H.5    Tsuchida, M.6
  • 11
    • 77953483479 scopus 로고    scopus 로고
    • Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial
    • Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-52.
    • (2010) Lancet Oncol , vol.11 , Issue.6 , pp. 543-552
    • Rubnitz, J.E.1    Inaba, H.2    Dahl, G.3    Ribeiro, R.C.4    Bowman, W.P.5    Taub, J.6
  • 12
    • 0035895057 scopus 로고    scopus 로고
    • Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: Results of the Japan infant leukemia study group
    • Kawasaki H, Isoyama K, Eguchi M, Hibi S, Kinukawa N, Kosaka Y, et al. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Blood. 2001;98(13):3589-94.
    • (2001) Blood , vol.98 , Issue.13 , pp. 3589-3594
    • Kawasaki, H.1    Isoyama, K.2    Eguchi, M.3    Hibi, S.4    Kinukawa, N.5    Kosaka, Y.6
  • 13
    • 34447282260 scopus 로고    scopus 로고
    • Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: Long-term outcome of the children with AML treated on two consecutive trials of tokyo children's cancer study group
    • Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, et al. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatr Blood Cancer. 2007;49(2):127-32.
    • (2007) Pediatr Blood Cancer , vol.49 , Issue.2 , pp. 127-132
    • Tomizawa, D.1    Tabuchi, K.2    Kinoshita, A.3    Hanada, R.4    Kigasawa, H.5    Tsukimoto, I.6
  • 14
    • 40649116451 scopus 로고    scopus 로고
    • Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients
    • Schmid I, Stachel D, Pagel P, Albert MH. Incidence, predisposing factors, and outcome of engraftment syndrome in pediatric allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant. 2008;14(4): 438-44.
    • (2008) Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant , vol.14 , Issue.4 , pp. 438-444
    • Schmid, I.1    Stachel, D.2    Pagel, P.3    Albert, M.H.4
  • 15
    • 33846862255 scopus 로고    scopus 로고
    • Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia
    • Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109(3):936-43.
    • (2007) Blood , vol.109 , Issue.3 , pp. 936-943
    • Lehrnbecher, T.1    Zimmermann, M.2    Reinhardt, D.3    Dworzak, M.4    Stary, J.5    Creutzig, U.6
  • 16
    • 77956400792 scopus 로고    scopus 로고
    • Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse
    • Ehlers S, Herbst C, Zimmermann M, Scharn N, Germeshausen M, von Neuhoff N, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol. 2010;28(15):2591-7.
    • (2010) J Clin Oncol , vol.28 , Issue.15 , pp. 2591-2597
    • Ehlers, S.1    Herbst, C.2    Zimmermann, M.3    Scharn, N.4    Germeshausen, M.5    Von Neuhoff, N.6
  • 17
    • 16544385748 scopus 로고    scopus 로고
    • Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98
    • Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384-93.
    • (2004) J Clin Oncol , vol.22 , Issue.21 , pp. 4384-4393
    • Creutzig, U.1    Zimmermann, M.2    Reinhardt, D.3    Dworzak, M.4    Stary, J.5    Lehrnbecher, T.6
  • 18
    • 67650106003 scopus 로고    scopus 로고
    • Infant acute lymphoblastic leukemia: Lessons learned and future directions
    • Pieters R. Infant acute lymphoblastic leukemia: lessons learned and future directions. Curr Hematol Malig Rep. 2009;4(3): 167-74.
    • (2009) Curr Hematol Malig Rep , vol.4 , Issue.3 , pp. 167-174
    • Pieters, R.1
  • 19
    • 0034235115 scopus 로고    scopus 로고
    • Biological and therapeutic aspects of infant leukemia
    • Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood. 2000;96(1):24-33.
    • (2000) Blood , vol.96 , Issue.1 , pp. 24-33
    • Biondi, A.1    Cimino, G.2    Pieters, R.3    Pui, C.H.4
  • 20
    • 28544445097 scopus 로고    scopus 로고
    • Long-term results of children with acute myeloid leukemia: A report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
    • Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ. Long-term results of children with acute myeloid leukemia: A report of three consecutive phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19(12):2054-62.
    • (2005) Leukemia , vol.19 , Issue.12 , pp. 2054-2062
    • Smith, F.O.1    Alonzo, T.A.2    Gerbing, R.B.3    Woods, W.G.4    Arceci, R.J.5
  • 21
    • 56749151167 scopus 로고    scopus 로고
    • Respiratory syncytial virus infections in children with acute myeloid leukemia: A report from the children's oncology group
    • Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, et al. Respiratory syncytial virus infections in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51(6):784-6.
    • (2008) Pediatr Blood Cancer , vol.51 , Issue.6 , pp. 784-786
    • Sung, L.1    Alonzo, T.A.2    Gerbing, R.B.3    Aplenc, R.4    Lange, B.J.5    Woods, W.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.